Presented by CDDF in collaboration with SITC: THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE
20 MARCH 22 2017 FINAL PROGRAMME PRAGUE CZECH REPUBLIC 5TH Immunotherapy Of Cancer Conference THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE cancer cell © vitanovski
MARCH 19-21, 2018
BERLIN, GERMANY
5TH EDITION MARCH 19-21, 2018 BERLIN, GERMANY
www.itoc-conference.eu SAVE THE DATE CORPORATE SATELLITE SYMPOSIUM GENERALINFORMATION PARTNERS EXHIBITORS ACKNOWLEDGMENTS FLOORPLAN POSTERS SCIENTIFICPROGRAMME PROGRAMME AT A GLANCE ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME) CONFERENCECOMMITTEE ORGANISINGPARTNERS CANCER DRUG DEVELOPMENT FORUM & PARTNERS WELCOMELETTER TABLE OF CONTENTS
PAGE 10 PAGE 16 PAGE 14 PAGE 21 PAGE 15 PAGE 17 PAGE 13 PAGE 8 PAGE 6 PAGE 6 PAGE 4 PAGE 5 PAGE 5 PAGE 7 OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY
3 FINAL PROGRAMME 4 FINAL PROGRAMME Conference President Prof. ChristophZielinski Yours sincerely, end oftheconferenceandpleasedonothesitatetoreachoutourteamonsiteorviaemail ([email protected]) Your ideasandsuggestionsonthefutureofthisconferencearewelcome.We thereforeencourageyou tocompletetheevaluation formatthe In addition,wewishtoexpressoursinceregratitudetheentirecommittee,organisingpartnersandsponsorsexhibitors. far beyond, andwewishyou avery successfulandenjoyable ITOC-4 inthebeautifulcityofPrague. The conferenceoffers abroadandexciting rangeofopportunities andtoolstogainexposureexpertsinvarious disciplineswithinEuropeand to provide aforumfordiscussionofearlyclinicaldrugdevelopment andaddressitsuniquechallenges. the efficiency of cancerdrug development andincooperation with Society forImmunotherapy ofCancer (SITC), theITOC conference series aim stakeholders (academia, regulatoryauthorities,policymakers, industry, patientadvocacy groupsandhealthtechnologyassessors) toimprove Organised by theCancerDrugDevelopment Forum (CDDF), whosemissionistoprovide auniqueplatformtofacilitateinteractionsbetweenall and Celltherapy. Regulation, Emergingconceptsandnovel targets,Combinationtherapy, Monitoringofimmuneresponseintheclinic,Therapeuticantibodies The scientificprogrammewithaninternationalfacultywillfocusonmanytopicssuchasPreclinicalmodels,Micro-environmentandImmune This meetinghasbeengrowingrapidlyintoaglobalplatformfortranslationalresearchinthefieldofimmuno-oncology. networking withincancerimmunotherapy. Welcome tothefourtheditionofImmunotherapy ofCancerconference (ITOC4), thepremiermeetingforeducation,scientificexchange and WELCOME LETTER OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY Conference President Prof. HowardKaufman Munich Tumour Center Prof. Volkmar Nüssler Scientific Chairman Prof. HeinzZwierzina n n n n Posterreviewing-Committee: n n n Winners areselectedby thescientificcommitteeaccordingtofollowingcriteria: access CDDF’slistofpublicationsat:www.cddf.org Meeting reportsandpublicationsbasedonpreviousworkshopsevents arefeaturedinsomeoftheleadingoncologyjournals.You may from academia,pharmaceuticalindustryandregulatoryauthoritiesinthequestofovercoming themainchallengesincancertreatment. For thepast14years, CDDFhasstrived toleverage thediscussionofmostpromisingadvances unitingexperts inoncologydrugdevelopment, effective oncologydrugdevelopment anddelivery. CDDF provides auniqueforumwhereallthosededicatedtothedevelopment ofcancerdrugscanexchange expertisetofindwaysexpedite ITOC4 POSTER PRIZE ORGANISING PARTNERS CANCER DRUG DEVELOPMENT FORUM n n n n n n n Prof. Dr. EricTartour (Hôpital EuropéenGeorges-Pompidou, France) Prof. Dr. LubosPetruzelka (Charles University, Czech Republic) Prof. Dr. BernhardFox (Providence Cancer Center, USA) Chairman: Prof. Dr. SebastianKobold Germany)(Ludwig-Maximilians-Universität, Ability oftheauthortopresentposterinaconciseandclearmanner andtoanswerquestionsduringthededicatedpostersessions. Novelty andoriginalityofresearch Scientific content/methodology EUR 1000,-/700,-/500,-. Prizes willbeawardedtothe threebestposterpresentations.Thewinnerswillreceive acertificateandprize of Conference thankstothegeneroussupportofTumor CenterMunich. We areproud toannouncetheITOC 4Poster Prize whichwillbeawarded atthe4thImmunotherapy ofCancer The CancerDrugDevelopment Forum (CDDF) isanot-for-profit organisationregisteredinAustria. breadth ofinterestsandactivities. forms ofcancerdrugdevelopment andthereforewantedanamethatbetterreflectstheorganisation’s While BDA’s focus was initially around immunotherapy, in recent years the association has embraced all Drug Development Forum (CDDF). It was established in 2001 as Biotherapy Development Association (BDA) and changed name in 2014 to Cancer OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY
5 FINAL PROGRAMME 6 FINAL PROGRAMME n n n n n n n n n n n n n n n n n n n n SCIENTIFIC COMMITTEE CHAIRMAN OF THE SCIENTIFIC COMMITTEE CONFERENCE PRESIDENTS EDUCATION (CME) ACCREDITATION FOR CONTINUOUS MEDICAL CONFERENCE COMMITTEE n n n n n n n n n n n n n n n n n n n n Rostislav Vyzula (Masaryk MemorialCancerInstitute,Czech Republic) Eric Tartour (Hôpital EuropéenGeorges-Pompidou, France) Mario Sznol (Yale Schoolof Medicine,USA) Zhen Su (Merck KGaA,Germany) Wenru Song (Chinese AmericanHematologyandOncologyNetwork,USA) Barbara Seliger (Martin LutherUniversity Halle-Wittenberg, Germany) Jose Saro (Roche, Switzerland) Lubos Petruzelka (Charles University, Czech Republic) Volkmar Nuessler (Munich Tumour Center, Germany) Zihai Li (Medical University ofSouthCarolina,USA) Sebastian Kobold Germany) (Ludwig-Maximilians-Universität, Samir N.Khleif (Georgia Regents University, UnitedStates) Robert F. Hawkins (The ChristieHospital,UnitedKingdom) Leif G.Hakansson (Universitetssjukhuset Linköping, Sweden) Fox Bernard A. (Providence CancerCenter, USA) Lisa H.Butterfield (University ofPittsburgh,USA) Ascierto Paolo A. (Istituto NazionaleTumori, Italy) Heinz Zwierzina (Innsbruck University, Austria) Kaufman Howard L. (Rutgers Cancer InstituteofNewJersey, USA) Christoph Zielinski (Medical University ofVienna,Austria) OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY The 4 to validate theircreditsinowncountry. European Accreditation is granted by the EACCME in order to allow participants who attend the above mentioned activity CME credits (ECMEC) by theEuropeanAccreditation CouncilforContinuingMedicalEducation (EACCME). th ImmunoTherapy ofCancerConference,Prague,Czech Republic (March 20–22,2017) hasbeengranted12European PROGRAMME AT A GLANCE 08:30 -10:00 14:00 -14:45 12:50 -14:00 14:00 -15:00 10:30 -11:00 12:50 -14:00 11:00 -12:50 14:45 -15:45 15:00 -15:30 11:00 -12:50 15:30 -17:40 10.30 -11.00 15:45 -16:15 17:30 -18:15 16:15 -17:25 Monday, March20, 2017 Tuesday, 2017 March21, 19:30 17:40 18:30 9:00 ITOC4 ConferenceDinner (Topics 1,3,4,5,6) Poster ViewingwithPresenters clinic (cont.) the Monitoring ofimmuneresponsein Plenary Symposium Coffee Break the clinic Monitoring ofimmuneresponsein Plenary Symposium Lifetime Achievement Award Lunch Combination therapy Plenary Symposium Coffee Break targets Emerging conceptsandnovel Plenary Symposium Satellite Symposium Lunch Preclinical models Opening PlenarySymposium Welcome Address Registration Opens Welcome Reception (Topic 2) Poster ViewingwithPresenters Regulation Micro-environmentandImmune Plenary Symposium Coffee Break
08:30 -09:30 09:30 -10:30 10:30 -11:00 11:00 -12:10 12:45 -13:30 Wednesday, March22,2017 12:15 Lunch Remarks Best Poster Awards & Closing Cell therapy Plenary Symposium Coffee Break Therapeutic antibodies Plenary Symposium Desert Tumor of ImmuneExcluded andImmune Plenary Symposium: Treatment OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY
7 FINAL PROGRAMME 8 FINAL PROGRAMME Benoit vandenEynde, Brussels,Belgium microenvironment Targeting immunosuppressive enzymesinthetumor 15:30 -15:50 Sweden OR,USA-LeifHakansson,Linköping, Fox,Portland, Chair: BernardA. Regulation Plenary Symposium -Micro-environmentandImmune 15:30 -17:40 Coffee Break 15.00 –15.30 page 21 Satellite Symposium –Forfurtherinformationpleasesee 14.00 –15.00 Lunch 12.50 –14.00 Annette Becker, USA (A21) Hayward,CA, tumor models positively affect anti-tumorimmunityinmousesyngeneic the presenceofexogenous AMP, affect tumorgrowthand in strongactivation ofhumanandmouseCD8+Tcellsin Small-molecule inhibitorsofecto-nucleotidaseCD73result 12:35 -12:50 Nadege Bercovici,Paris,France (A9) mammary tumor-bearing mice Tumor regressioninducedby typeIinterferontriggeringin 12:20 -12:35 OR,USA Fox,Portland, Bernard A. Multispectral imagingofthetumourenvironment 12:00 -12:20 OR,USA David Page,Portland, genomics data autophagosome vaccine usingimmunomonitoringand Preclinical andearlyclinicaldevelopment ofan 11:40 -12:00 Mario Sznol,NewHaven,CT, USA The needforpreclinicalmodelsimmunotherapy 11:10 -11:40 Welcome Address –11.10 11.00 Innsbruck, Austria Chair: HowardKaufman, NewBrunswick,NJ,USA-HeinzZwierzina, translational research Opening PlenarySymposium -Preclinicalmodelsand –12.5011.00 Christoph Zielinski,Vienna,Austria Welcome Address 10.30 -11.00 MONDAY, 20, 2017 MARCH SCIENTIFIC PROGRAM OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY
Andreas Spitzmüller, Munich, Germany (A3) treated withDurvalumab A predictive PD-L1*CD8cell densityscoreforNSCLC patients 17:25 -17:40 Leuven,Belgium (A17)Thais Baert, determine outcomeinovarian cancer Monocytic myeloid derived suppressorcells (mMDSC) 17:10 -17:25 Lorenzo Moretta,Rome,Italy therapy NK cellsinthetumormicroenvironment-implicationsfor 16:50 -17:10 Zihai Li,Charleston,SC,USA Control ofregulatoryTcellfunction 16:30 -16:50 Ignacio Melero, Navarra,Spain microenvironment Mechanisms ofexhaustioninT-Cells andtumor 16:10 -16:30 Greg M.Delgoffe, USA Pittsburgh,PA, Overcoming metabolicbarrierstoantitumorimmunity 15:50 -16:10 Andrea Facciabene, Philadelphia, PA, USA Andrea Facciabene,Philadelphia,PA, (B1) renal cellcarcinoma A tumormitochondriavaccine protectagainstexperimental 10:00 -10:15 Michael vonBergwelt-Baildon, Cologne, Germany Therapeutic targetingofBcells 09:40 -10:00 Marij Welters,Leiden,Netherlands Vaccination duringmyeloid celldepletion 09:20 -09:40 Niels Halama,Heidelberg,Germany immunotherapy Targeting CCR5 formacrophagerepolarizationcancer 09:00 -09:20 Aurélien Marabelle,Paris,France development Novel targetsandapproachesforimmunotherapy 08:30 -09:00 USA Chair: SamirKhleif, USA-WenruSong,Arlington,MA, Augusta,GA, Plenary Symposium -Emergingconceptsandnovel targets 08:30 -10:00 Welcome Reception 18.30 Posterviewing withPresenters (Topic 2) 17.40 TUESDAY,MARCH 21, 2017 Paolo Ascierto,Naples,Italy Are immune-mediatedadverse events reallyautoimmunity? 15:05 -15:25 Michele Maio, Siena, Italy Epigenetic immunomodulationforcancerimmunotherapy 14:45 -15:05 Chair: EricTartour, Paris,France-ChristophZielinski,Vienna,Austria clinic Plenary Symposium -Monitoringofimmuneresponseinthe JOINT ESMO-ITOC Session 14:45 -17:25 Thierry Boon,Brussels,Belgium and toxicity Cancer immunotherapy: thenarrowroadbetweeninefficacy Lifetime Achievement Award 14.00 –14.45 Lunch 12.50 –14.00 Mesha Saeed,Rotterdam,Netherlands (A40) A1 TCR-like scFvforimproved drugdelivery tomelanoma Doxorubicin loadedimmunoliposomescoupledtoanti-MAGE 12:35 -12:50 Netherlands (B2) Amsterdam, C. WillemienMenke-vanderHouvenvanOordt, manner CEA-mediated tumoraccumulationinadose-dependent patients withsolidtumors:roleofIL-2 receptor-binding and 89Zr-labeled CEA-targetedIL-2 variant immunocytokinein 12:20 -12:35 Angus Dalgleish,London,UnitedKingdom Immunogenic chemotherapy 12:00 -12:20 Neyns,Brussels,Belgium Bart inhibition Dendritic celltherapy incombinationwithcheckpoint 11:40 -12:00 Samir Khleif, USA Augusta,GA, Combining vaccination withinhibitionofTcellsignaling 11:20 -11:40 USA Boston,MA, Ott, Patrick A. Combination ofCheckPoint BlockadeforCancerTherapy 11:00 –11:20 Chair: ZihaiLi,Charleston,SC,USA-PaoloAscierto,Naples,Italy Plenary Symposium -Combinationtherapy 11:00 -12:50 Coffee Break 10.30 –11.00 Sabrina Yu-Sang Yang, USA Cambridge,(A36) MA, ultra-small amphiphilicNanoparticles In vivo targetingofTGF-beta inhibitorstoCD8+Tcellsvia 10:15 -10:30 17:10 –17:25 Jeffrey Weber, NewYork, NY, USA (A31) immunotherapy incancerPatients Proteomic testidentifiessensitivityandresistanceto 16:50 -17:10 Tanushree Jaitly, Erlangen,Germany (A46) Personalized Tumor EpitopesinCancer An ImmunoinformaticsFrameworkforIdentificationof 16:35 -16:50 Graham Ball,Nottingham,UnitedKingdom genomic approaches Identification ofbiomarkers usingcombinedproteomicand 16:15 -16:35 clinic (cont.) Plenary Symposium -Monitoringofimmuneresponseinthe Coffee Break 15:45 –16:15 Eric Tartour, Paris,France immunoflourescence inoncology Prognostic andpredictive value ofmultiplexinsitu 15:25 -15:45 Germany Chair: SebastianKobold, Munich,Germany- Barbara Seliger, Halle, Plenary Symposium -Therapeutic antibodies 09:30 -10:30 Lana Kandalaft, Lausanne,Switzerland Approaches Combinatorial Immunotherapy andAnti-Angiogenic 09:10 -09:30 Lei Zheng,Baltimore,MD, USA Microenvironment Challenges andOpportunitiesforReprogramming theTumor 08:50 -09:10 Stefani Spranger, Cambridge, MAUSA microenvironment The roleofBatf-3 DCinthenon-T cell-inflamedtumor 08:30 -08:50 Chair: PaoloAscierto Treatment ofImmuneExcluded andImmuneDesertTumors 08.30 –09.30 ITOC4 Conference Dinner 19.30 Posterviewing withPresenters (Topics 3,4,5,6) 1, 17.30 –18:15 Lenka Zdrazilova-Dubska, Brno, CzechRepublic (A34) single institutionreal-lifedataexperience of advanced melanomapatientstreatedwithipilimumab: Baseline peripheralbloodbiomarkers predict clinicaloutcome WEDNESDAY,MARCH 22, 2017
OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY
9 FINAL PROGRAMME 10 FINAL PROGRAMME Lunch 12.45 –13.30 Best Poster Awards & ClosingRemarks 12:15 Sebastian Kobold, Munich,Germany A novel platformforMHC-unrestricted adoptive Tcelltherapy 11:50 -12:10 Els Verdegaal, Leiden,Netherlands Editing ofneoepitopesduringTcelltherapy 11:30 -11:50 Hawkins,Manchester,Robert UnitedKingdom Pre-conditioning chemotherapy andcytokinessupport? T-cell therapy -whathave welearnedabouttheroleof 11:00 –11:30 Munich, Germany Hawkins,Manchester,Chair: Robert UnitedKingdom–StefanEndres, Plenary Symposium -Celltherapy 11:00 -12:10 Coffee Break 10.30 –11.00 Narjara GonzálezSuárez,Havana,Cuba (A43) endogenous polyclonal antibodies simultaneous inactivation ofHER1 & HER2through Anti-proliferative & pro-apoptoticeffects inducedby 10:10 -10:25 Frank Nimmerjahn,Erlangen,Germany therapeutic approaches Translating inhibitoryFcreceptorbiologyintonovel 09:50 -10:10 Yang USA XinFu,Dallas,TX, triggering Tumour targetingantibodies:fromtumorkillingtoimmunity 09:30 -09:50 POSTER PRESENTATIONS 1. PRECLINICAL MODELS A4 A2 B3 A1 OF CANCER CONFERENCE 4 TH immunotherapy Assessing humanized mousemodelsforcancer Tomokazu Kyoto, Aoki, Japan vivo glioma celllineresultsinreducedtumorigenicity Expression ofmurineinterleukin7ina Jan Ženka, melanoma model Intratumoral immunotherapy. B16-F10murine Stefan Koeck, Innsbruck, Austria subpopulations microtissue infiltratingcytotoxic Tlymphocyte The influenceofspecificcytokines oncancer Laure Loumagne,Vitry, France IMMUNOTHERAPY Č eske Bud ě jovice, CzechRepublic
2. TUMOR IMMUNITY AND MICROENVIRONMENT LB1 A8 A7 A6 A5 B5 A16 A15 A14 A13 A12 A11 A10 B4 Michael Ruzicka,Munich,Germany acute myeloid leukemia Immunotherapy targetingRIG-Iinamousemodelof Munich,Germany Caroline Plett, blasts reliable marker todetectandquantifyproliferating proliferation exvivo: IPO-38isanappropriateand Immunomodulatory KitsdonotinduceAML-blasts’ Halle,Germany Dagmar Quandt, and theinflammasome marker ondendriticcellsindependentofexCalcium Doxorubicin increasesTLR4triggeredactivation Frank Xing,Taicang, Jiangsu,China system withmouseTcells combination withtargetedagentsinacoculture mouse celllinestestingcheckpointinhibitorsin Genomic profilingandinvitroscreenofsyngeneic Matteo Riva,Leuven,Belgium murine highgradeglioma A strategytoimprove thetranslationalimpactof Alexander Baumann, Birmingham,UnitedKingdom Development inCancerImmunotherapy BioMAP® Systems forDrugDiscovery and Profiling CompoundsinHuman PrimaryCell An Coosemans, Leuven, Belgium ovarian cancerpatients Relevance of systemicimmunosuppressionin Richard Klar, Germany Martinsried, microenvironment oligonucleotides formodulationofthetumor Targeting hIDO1with3rdgenerationantisense MexicoCity, Prado-Garcia, Heriberto Mexico lung cancerpatients Mitochondrial massanalysisinCD8+Tcellsfrom Gabriele Gamerith,Innsbruck,Austria lung tissueandwholeblood analyses ofimmunologicalsubpopulationsintumor, The immunomeinearlystageNSCLC: flowcytometry Tamara Germany Hilmenyuk,Planegg/Martinsried, against tumors antisense oligonucleotidestoimprove immunity Inhibition ofCD39andCD73by 3rdgeneration Anamarija Markota,Munich,Germany methycholanthren-A-mediated tumorigenesis Interleukin-22 (IL-22) doesnotinfluence Daniel Amberger, Munich,Germany blood fromhealthyvolunteers orpatientswithAML T-cell reactivityfrommononuclearcellsorwhole derived) dendritic cellsthatimprove antileukemic A newmethodtogeneratemature (leukemia- Jan Spacek,Prague,CzechRepublic cancer Immunomonitoring ofthepatienswithcolorectal LB2 A29 A28 A27 A26 A25 A24 A23 A22 B7 A20 A19 B6 A18 Meggy Suarez-Carmona, Heidelberg,Germany Immune-related effects ofthe fatinovarian cancer Christian Merz,Heidelberg, Germany mouse modelsofcolorectalcancer anti-tumour responseofeffector T-cells insyngeneic Hexavalent CD27agonistHERA-CD27Lenhances Kj SenthilKumar, Taichung, Taiwan and metastasisviaNF- of miRNA-708 modulatesbreastcancerproliferation Glucocorticoid receptoragonist-mediated induction Erlangen,Germany Carol ImmanuelGeppert, Biomarkers? Digital Pathology -aKey toDiscover new Stephanie McArdle,Nottingham,UnitedKingdom transcriptomic andphenotypicanalysis cell subsetsinpatientswithbreastcancer:A Effects ofneoadjuvant chemotherapy onimmune Mariana Pinho, SãoPaulo, Brazil donors by Tcellsofbreastcancerpatientsandhealthy Recognition oftumor-associated self-protein Her2 Christian Merz,Heidelberg,Germany anti-tumour activity induced celldeathwithoutcompromisingtheir compound protectsimmunecellsfromactivation- Asunercept (APG101) aCD95L-neutralizing Irene Gullo, Porto,Portugal microenvironment andPD-L1status virus, microsatelliteinstability, tumourimmune of clinico-pathologicalprofile,Epstein-Barr Gastric cancerwithlymphoidstroma:Astudy Shuai Yin,Muenchen,Germany prognosis ofcolorectalcancerpatients Aberrant statusofglutathionemetabolismpredict Bjoern Wendik,Rodgau,Germany sections multiple immunecellsubsetsin-situinFFPEtissue Imaging incancerimmunology:Phenotypingof Chris Allen,SouthSanFrancisco, UnitedStates solution matched freshfrozen samplesusingatargetedNGS microenvironment from40NSCLC FFPEand Gene expressionprofileofthetumor Lenka Zdrazilova-Dubska, Brno, CzechRepublic patients are increasedinbreastandcolorectalcancer Circulating myeloid-derived suppressorcells (MDSC) Xiaohui Shen,Shanghai,China ERK/NF- CCR4 activated by TNF- Johannes Laengle,Vienna,Austria and confersbetterprognosis associates withincreasedCD8+lymphocyteinvasion GBP1 expressionincolorectalcancerliver metastasis κ B pathwayincoloncancer κ α B signalingpathway facilitatemetastasisvia 3. 4. COMBINATION THERAPY LB4 A35 B8 A33 A32 A30 B10 A42 A41 A39 A38 A37 B9 THERAPEUTIC MODULATION AND MONITORING OF IMMUNE RESPONSE Pretreatment ImmuneStatusisapredictionmarker D Aguilar-Cazares, MexicoCity, Mexico overall survival inlungadenocarcinomapatients HMGB1 plasmaconcentrationsareassociatedwith Shinji Osada,Gifu,Japan cryoablation Therapeutic effect ofimmunereactiondueto Young-Chul Kim,Jeonnam,RepublicofKorea Treatment ofNon-SmallCellLungCancer Clinical ExperienceofNivolumab asaSecondLine Corinna Boeck,Munich,Germany and CLL ALL is predictive foroutcomeofpatientswithAML, of (DC-stimulated) invariant NKT-, NK- andCIK-cells Number, compositionand/or antileukemic activity Lan Zhang,Taicang, China efficient manner syngeneic modelsforinvivo screeninginahigh- MuScreenTM :apanelofwell-characterized Petr Hausner, Baltimore,UnitedStates immune checkpointblockade Radiation recallpneumonitisinduced by double Erlinda Gordon,SantaMonica,United States advanced soft tissuesarcoma administration oftrabectedinandnivolumab in Cancer immunotherapy withsequential Sana Javed,Hamburg,Germany cells Synergistic effects ofP2X7anddoxorubicin intumor Ralf Kleef, Vienna,Austria interleukin-2 (IL-2) andfever rangehyperthermia combining low-dosecheckpointinhibitorswith Complete responseofstageIIIBesophagealcancer Rodolfo Chavez-Dominguez, MexicoCity, Mexico agents adenocarcinoma celllinestreatedwiththerapeutic Study ofimmunogeniccelldeathmarkers in lung Barbara Volz, Berlin,Germany models combination withcheckpointinhibitorsintumor The dSLIMfamilyofTLR9agonists-benefitthe Shinji Osada,Gifu,Japan progression of pancreaticfibrosistoestimatepancreascancer The significanceofhistopathologicalevaluation Yuji Heike,Tokyo, Japan treated metastaticcolorectalcancerpatients of progression-freesurvival inchemotherapy OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY
11 FINAL PROGRAMME 12 FINAL PROGRAMME 6. ADOPTIVE CELL THERAPY 5. ANTI-CANCER VACCINES LB5 A48 B11 A47 A45 A44 OF CANCER CONFERENCE 4 TH Sarah Matko, Dresden,Germany cell therapy ofrelapsedleukemia Individuals implicatesnewstrategiesforadoptive t LAA-specific cytotoxic T lymphocytes inhealthy Detection ofhighlyprevalent andfunctional Bruno LoureiroCadilha, München,Germany pancreatic tumormodel receptor 2enablesTcellactivityinamurine Dominant negative tumor growthfactorbeta Felicitas Rataj,Munich,Germany antibody redirectedlysisofcancercells Arming Tcellswithactivating Fc Felicitas Rataj,Munich,Germany Hodgkin Lymphoma receptor forTcell-basedimmunotherapy ofNon- Preclinical characterizationofaPD-1-CD28 fusion Tone Otterhaug,Oslo, Norway vaccines for therapeuticeffect ofpeptide-andproteinbased enhancing cellularimmuneresponsesimportant internalisation (fimaVacc) -anovel technologyfor Phase Iclinicalstudyforvalidation ofphotochemical Célia Jacoberger-Foissac, Illkirch,France cancer therapy like andNod-like receptorssynergyfortargeted Development ofanovel immunotherapy withToll- IMMUNOTHERAPY γ RIIIa receptorsfor FLOORPLAN -LEVEL 2 -PCC
ITOC P R
ITOC M H
Topic 4 Topic 5 Topic 6 Topic 4 Topic 3
Topic 2
Topic 2 ITOC
opic 2 E C T Topic 1 (Forum Hall Foyer 2) ITOC4 R
O
T OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY Poster boards: Topic 1. Preclinical models = 9 Posters Topic 2. Tumor Immunity and Microenvironment = 23 Posters Topic 3. Therapeutic modulation and monitoring of immune response = 7 Posters Topic 4. Combination therapy = 7 Posters Topic 5. Anti-cancer vaccines = 2 Posters Topic 6. Adoptive cell therapy = 4 Posters TOTAL = 52 Posters 13 FINAL PROGRAMME 14 FINAL PROGRAMME Conference (ITOC4). The ITOC4 OrganisingCommitteewishestogratefullyacknowledgeoursponsorsandexhibitorsforsupportingthe4 We thankallITOC4 sponsorsandpartners. n n n For questionsregardingsponsorshipandexhibition,pleasecontactRose International. SPONSORS SPONSORS-EXHIBITORS-PARTNERS ACKNOWLEDGMENTS n n n Telephone: +3170 3838901 E-mail: [email protected] Contact: Floravan Laer OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY analytical challenges, improve patientdiagnosticsandincrease laboratoryproductivity. the worldhealthier, cleanerandsafer. We helpourcustomersaccelerate lifesciencesresearch,solve complex Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the nCounterDxAnalysisSystem whichisFDA 510(k) cleared. System. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is marketed for use on in 1,000+ peer reviewpublications,hasalsonowbeenappliedtodiagnosticusewiththenCounterDxAnalysis AnalysisSystem, whichhasbeenemployed inbasicandtranslational researchandcited The company’snCounter® NanoString Technologies provides lifesciencetoolsfortranslationalresearchandmoleculardiagnosticproducts. 1,700 employees in25countries. of expertiseincludesimmunology, stemcellbiology, neuroscience,andcancer. MiltenyiBiotechasmorethan support researchfrombasictotranslational clinical application.Ourmorethan25years Miltenyi Biotecprovides productsthatadvance biomedicalresearchandcellulartherapy. Ourinnovative tools better forallthoseaffected by canceraroundtheworld. with cancerandthosewhocareforthem.Lillyisdeterminedtobuildonthisheritagecontinuemakinglife For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living clinical portfoliothatincludes14development candidatesagainst11different moleculartargets. commitment to improving the lives of patients with cancer and other diseases. Incyte has a broad and diverse of proprietarytherapeutics.World-class scienceandthepursuitofR&Dexcellence drive Incyte’sbusinessandits Incyte Corporationisabiopharmaceuticalcompanyfocusedonthediscovery, development andcommercialization around theworldintheirfightagainstcancer, cardiovascular disease,hepatitis C,HIVandrheumatoidarthritis. innovative medicinesthathelppatientsprevail over seriousdiseases.Our medicinesarehelpingmillionsofpeople Bristol-Myers Squibbisaglobal biopharmaceuticalcompanywhosemissionistodiscover, develop anddeliver MILTENYI BIOTEC LILLY ONCOLOGY INCYTE CORPORATION BRISTOL-MYERS SQUIBB THERMO FISHER SCIENTIFIC NANOSTRING
View moreon View moreon View moreon To learnmoreaboutLilly’scommitmenttopeoplewithcancer, pleasevisit View moreon View moreon www.incyte.com www.bms.com www.nanostring.com www.miltenyibiotec.com www.thermofisher.com www.lillyoncology.com th Immunotherapy of Cancer Immunotherapy ofCancer EXHIBITORS Consortium (CIMT), Immudexalsoprovides MHCMultimerandElispot proficiencypanelservicesworldwide. an agreementwiththeUSCancer Immunotherapy Consortium (CIC) and the EuropeanCancerImmunotherapy cells inlifescienceresearch,vitro diagnostics,andthedevelopment ofimmunotherapeuticsandvaccines. Under T Based inCopenhagen,Denmark,Immudex manufacturesMHCDextramersforthedetectionofantigen-specific discovery throughpreclinicaldevelopment. BioMAP® brands,enablesrapiddevelopment ofsafeandeffective biologic andsmallmoleculedrugsfromearly Theindustry-leadingportfolioofproductsandservices,undertheKINOMEscan®,development. and PathHunter® DiscoverX Corporationistheleadingsupplierofinnovative cell-based assaysandservicesfordrugdiscovery and systems, enableclientstodeliver superiorclinicalcandidates. models, comprehensive Translational Platform,andimmunotherapy modelsincludingsyngeneicandhumanized Oncology andMetabolicDisease.Ouruniquecollectionofready-to-run, well-validated invitro, invivo, exvivo Crown Bioscience,Inc.isaplatformtechnologycompanyproviding drugdiscovery anddevelopment servicesin agents topatients. of oncologydrugs.Theaimthenot-for-profit organizationistoacceleratethedelivery ofeffective oncology The (CDDF) isaninternationalorganizationproviding aplatformforallstakeholders involved inthedevelopment in Prague. We will be available tomeetyou attheexhibition area, feel free to come and visitusatanytime! CDDF looksforwardtowelcomingyou atthe4theditionofImmunotherapy ofCancerConference (ITOC4) and conjugation.BioLegendiscertifiedforISO9001:200813485:2003. immunology, neuroscience, cancer, sampletesting, andstemcells.Customservicesincludeassaydevelopment, value. Thebroadproduct portfolio includes flow cytometry, cellbiology, and functional reagents forresearch in BioLegend develops andmanufacturesworld-class,cutting-edge antibodiesandreagentsatanoutstanding data interpretationfromsuperiorandexperiencedscientists. efficacy andmechanismofactiondrug/antibody candidates. Partner withustobenefitfromexpertadviceand combining advanced modelswithprotocolledtechniques.Theresult?High-value dataallowingyou todefine research expertiseinimmuno-oncology, immunologyandmultiplexhistology. We offer bespoke services, Aquila BioMedicalisaninnovative, preclinicalcontractresearchorganisation,offering clientsworld-leading as proteindirectedapproaches. OriGene EUisyour “1stopsolutionprovider”. We supportyou ascancerresearchscientistsinyour geneaswell lysates, proteins, antibodies and many more. Acris Antibodies- and protein based research: cDNA clones, siRNA, Acris Antibodiesacquiredby OriGenerecently, offer >1 millionresearchproducts–everything you needforgene specific website). policies, programsandpartnerships.Formoreinformation,visitwww.msd.com orwww.msd.XX (for country- health solutions.We alsodemonstrateourcommitmenttoincreasingaccesshealthcarethroughfar-reaching animal healthproducts,weworkwithcustomersandoperateinmorethan140countriestodeliver innovative of Merck & Co.,Throughourprescriptionmedicines,vaccines, Inc.,Kenilworth,biologictherapies,and N.J.,USA. For over acentury, MSDhasbeenaglobalhealthcareleaderworkingtohelptheworldbewell.istradename MSD CROWN BIOSCIENCE THE CANCER DRUG DEVELOPMENT FORUM (CDDF) BIOLEGEND AQUILA BIOMEDICAL ACRIS ANTIBODIES IMMUDEX DISCOVERX
View moreon View moreon View moreon View moreon visit View moreon View moreon View moreon www.msd.com www.immudex.com www.discoverx.com www.crownbio.com http://cddf.org www.biolegend.com www.aquila-bm.com www.acris-antibodies.com or www.msd.XX or
cddf_eu (for country-specificwebsite) OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY
15 FINAL PROGRAMME 16 FINAL PROGRAMME PARTNERS OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY clinical portfoliothatincludes14development candidatesagainst11different moleculartargets. commitment to improving the lives of patients with cancer and other diseases. Incyte has a broad and diverse of proprietarytherapeutics.World-class scienceandthepursuitofR&Dexcellence drive Incyte’sbusinessandits Incyte Corporationisabiopharmaceuticalcompanyfocusedonthediscovery, development andcommercialization For moreinformation,pleasevisit analytical challenges,improve patientdiagnostics andincreaselaboratoryproductivity. the worldhealthier, cleanerandsafer. We helpourcustomersacceleratelifesciencesresearch,solve complex Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make SITC bringstogetherallaspectsofcancerimmunologyandimmunotherapy. cancer immunotherapy. Throughemphasisonhigh-caliberscientificmeetings,education,andcollaborations, the worldwhoarededicatedtoimproving cancerpatientoutcomesby advancing thescienceandapplicationof SITC isa501 (c)(3)1,600 non-profitprofessionalsocietyof over influentialscientistsandpractitionersfromaround being atrustedpartnerwithinthescientificcommunity. Pleasecontact:[email protected] developed and refined innovative protocolsto ensure quality, reliabilityandconsistency. We pride ourselves on Withoverquality cytokineproductsforthelife-scienceandcelltherapy market. 2,000 productsPeproTech has PeproTech isaprivately ownedbiotechnologycompanyfocusingonthedevelopment andmanufactureofhigh the nCounterDxAnalysisSystem whichisFDA 510(k) cleared. System. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is marketed for use on in 1,000+ peerreviewpublications,hasalsonowbeenappliedtodiagnosticuse withthenCounterDxAnalysis Analysis System, which hasbeenemployed inbasicandtranslationalresearchcited The company’snCounter® NanoString Technologies provides lifescience toolsfortranslationalresearchandmoleculardiagnosticproducts. research relatedtoallergy, apoptosis,autophagy, cancer, epigenetics,immunology, andneuroscience. monoclonal andpolyclonal antibodies,MHCtetramers,fluorescentandrecombinantproteinsELISAkitsfor products forlifescienceresearchandclinicaldiagnostics.MBLIdevelops andmanufacturesabroadportfolioof MBL Internationalisalifesciencecompanyfocusedonproviding highquality, innovative, solutions-based immuno-oncology alliance will jointly develop and commercialize avelumab PD-1 and advance antibody. Pfizer’s potential ofavelumab, aninvestigational anti-PD-L1antibodyinitiallydiscovered anddeveloped by Merck.The strengthsandcapabilities andfurtherexplorethetherapeutic enables thecompaniestobenefitfromeachother’s Immuno-oncology isatoppriorityforMerckandPfizer. TheglobalstrategicalliancebetweenMerckandPfizer TUMORZENTRUM MÜNCHEN – TZM (MUNICH TUMOUR CENTRE) THERMO FISHER SCIENTIFIC THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) PEPROTECH NANOSTRING MBL INTERNATIONAL MERCK-PFIZER ALLIANCE INCYTE CORPORATION THE CHINESE AMERICAN HEMATOLOGIST AND ONCOLOGIST NETWORK (CAHON) THE SOCIETY FOR IMMUNTHERAPY OF CANCER (SITC)
View moreon View moreon View moreon View moreon View moreon View moreon View moreon View moreon View moreon www.sitcancer.org www.peprotech.com www.nanostring.com www.mblintl.com www.merckgroup.com www.incyte.com www.tumorzentrum-muenchen.com www.sitcancer.org www.thermofisher.com http://cahon.org or sitcancer
For furtherinformationonpublictransportationpleasesee: access by publictransportfromthecity’sairportandallmajorrailbusstations. The PragueCongressCentreisadjacenttotheVyšehradstationonLineCofundergroundrailwaynetwork,providing convenient www.kcp.cz Telephone: +420261171111 Adress: 5.kvetna 65–CZ-14021 Prague,Czech Republic Exhibition Area:ForumHallFoyer, level 2 Prague CongressCentre Telephone: +3170 3838901 E-mail: [email protected] Contact: Floravan Laer Exhibition Management & CongressConsultancybv Telephone: +431405138318 E-mail: [email protected] Contact: CatherineTomek Vienna MedicalAcademy Website: Email: [email protected] Phone: +32 (0)2 7750215 1200 Brussels,Belgium Avenue E.Mounier83 The CancerDrugDevelopment Forum (CDDF) SPONSORSHIP AND EXHIBITION MATTERS CONFERENCE MATTERS SECRETARIAT HOW TO REACH THE VENUE CONFERENCE VENUE SECRETARIATS GENERAL INFORMATION www.cddf.org
www.kcp.cz/en/travel-to-pcc
OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY 17 FINAL PROGRAMME 18 FINAL PROGRAMME IMPORTANT: 3 2 1 different fee applies for onsite payments and registrations. Registering beforeadeadline Reduced registrationfeesareonlyapplicable,iftheyhave beencreditedtothecongressaccountbeforerespective deadlines. Any replacement (i.e. changeofdelegatename) ofaconfirmed registrationissubjecttoa50EURchargeperparticipant. Replacements n 2017:50%refund before January31, The followingrulesapply: E-Mail: [email protected] orFax:+4314051383918canbeaccepted. Please notethatonlywrittencancellationsaddressedtoITOC4 c/o ViennaMedicalAcademy, AlserStraße4,1090Vienna,Austriaeitherper Cancellations n n n n n What iscovered by theregistrationfee? deadline expiresthefeewillbechangedtonextapplicableautomatically. Registration feesinEuro n n n Registration Hours REGISTRATION
The “Junior Participant” registrationisavailableforStudentsunder30yearsofage.PleaseprovideacopystudentIDatthemomentyourregistration. The “JuniorParticipant” A PressIDconfirmingyourstatusmustbeprovidedatthemomentofregistration. your onsiteregistration. Please provide the SITC Promotional Code duringonsite registration. Note: the reducedregistration fee only applies if the code is provided –make sure to inquire with SITC prior to participants Conference Dinnerforregistered participants Welcome Reception forregistered Press/Media Pass Registration SITC Member–JuniorParticipant SITC Members–Academia Industry Junior Participant Academia n n n n n n n n n after January 31, 2017:norefund after January 31, Admission toexhibition Coffee breaks & Lunches Welcome reception (no feebutregistrationmandatory) Abstract bookandprogramme Admission toallscientificsessions Wednesday, March22,2017 Tuesday, 2017 March21, Monday, March20, 2017 OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY Payment received: 1 ...... 2 ...... 3 withoutperforminganactualpaymentwasnotsufficient tobenefitfromthereduction.Pleasenotethat a 1,2 09:00 -18:30hrs 08:00 -13:30hrs 07:30 -18:30hrs until December15,2016 If the fee is not transferred to the congress bank account before the respective Early Bird 450,- 380,- 100,- 750,- 120,- No Fee,butregistrationismandatory Free ofcharge 65,- to March10, 2017 December 16 480,- 850,- 550,- 150,- 130,- On-Site 650,- 950,- 580,- 155,- 175,- Contribution towardsexpenses:EUR65,- Website: Conference dinnerattheSacréCoeur Tuesday, 2017 March21, No feeforregisteredparticipants,butregistrationismandatory! Welcome CocktailintheexhibitionareaofPragueConferenceCenter Monday, March20, 2017 at theITOC4. to all registered participants right after the conference. It is possible to claim a maximum of 12 CME points for attendance of scientific sessions confirmation stating the according number of CME credits after finishing a survey requested by the UEMS. The link to the survey will be sent The 4 Coffee breaks,lunchesandawelcomereceptionhave beenscheduled.Exacttimesarelistedintheprogrammeoverview. times duringtheconference. For securityreasons,badgeswillbechecked uponaccessoftheconferenceareas.Delegatesarethereforerequestedtoweartheirbadgeatall NETWORKING EVENTS CERTIFICATE OF ATTENDANCE CATERING BADGES th ImmunoTherapy ofCancerConferenceishappy tointroduceadigitalCMEacquisitionsystem.You willbeabletoviewandprinta www.sacrecoeur.cz OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY 19 FINAL PROGRAMME 20 SAVEFINAL PROGRAMME THE DATE the ITOC restrictionswhereappropriate. the ITOC conferencescientificprogramme,theyshouldbeaccompanied by aqualifiedhealthcareprofessionalor ITOC representative observing adult atalltimesandobserve therestrictionsthatapplytolimitedaccessareas.Inevent thatamemberofpublicisinvitedtoparticipatein any sessionsorpracticaldemonstrations.Intheevent thatchildrenarerequiredtoentertheconferencecentre,theyshouldbesupervisedby an an industry activity. In addition, the ITOC-4 conference asks delegates and faculty to refrain from taking children and accompanying adults to ITOC4 isaccessibletoallregistereddelegates.Childrenandmembersofthepublicarenotpermittedinexhibitionareaoranyroom hosting theft ornegligence. All enquiries shouldbe directedtothe registration deskinthe entrancehall ofLevel 2. The organizers accept noresponsibility for lossdueto The official languageoftheconferenceisEnglish.Nosimultaneoustranslationprovided. Participants arerequestedtomake theirownarrangementsforhealthandtravel insurance.Theconferencefeedoesnotinclude By registeringtotheITOC4 participantsagreethatneithertheorganisingcommitteenorcongressoffice assumeanyliabilitywhatsoever. professionals, pressandexhibitors. The exhibitionisheldinthe Forum Hall Foyer 2ofthe Conference Center. Entranceisfreefor registered delegates butlimited tohealthcare POLICIES LOST &FOUND LANGUAGE &TRANSLATION INSURANCE EXHIBITION OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY 2017 Richard V. Smalley, MDMemorialAward andLectureship Recipient Paul M. Sondel, MD, PhD–University of Wisconsin, Madison Keynote Speaker SUBMISSION ABSTRACTS CALL FOR APRIL 3 OPENS 2017 SITC & ConventionCenter Gaylord NationalHotel MARYLAND NATIONAL HARBOR November 8-12 sitcancer.org/ SITC-0117-631 SATELLITE SYMPOSIA
OfficialText? ITOC4 Sponsored Satellite Symposium Cross-Disciplinary Insights and Emerging Tools of the Trade for Immuno-Oncology Monday, 20 March 2017 | 14:00–15:00 Prague Congress Centre Forum Hall Prague, Czech Republic
Programme: PD-L1—Friend or Foe? A Pathologist’s Perspective Aleš Ryška, MD, PhD Charles University Medical Faculty and University Hospital Hradec Králové, Czech Republic
A Radiation Oncologist’s View of Immunotherapy David Feltl, MD, PhD, MBA General University Hospital CALL FOR Prague, Czech Republic ABSTRACTS SUBMISSION OPENS SITC The Role of Molecular Markers— APRIL 3 A Medical Oncologist’s Perspective Luboš Petruželka, MD, PhD 2017 First Faculty of Medicine, Charles University and November 8-12 General University Hospital NATIONAL HARBOR Meeting Chair Prague, Czech Republic MARYLAND Gaylord National Hotel & Convention Center Panel discussion and audience Q&A to follow presentations sitcancer.org/ Bristol-Myers Squibb: Official Sponsor 4th Immunotherapy of Cancer Conference (ITOC4) Keynote Speaker Paul M. Sondel, MD, PhD – University of Wisconsin, Madison SITC-0117-631 2017 Richard V. Smalley, MD Memorial Award and Lectureship Recipient IOCZ17NP00418-01 02/17 © 2017 Bristol-Myers Squibb Company SAVE THE DATE SAVE
BMOPUS17X047_LUNG_HQ_Med_ITOC_AD_R07.indd 1 2/3/17 11:25 AM 22 FINAL PROGRAMME NOTES OF CANCER CONFERENCE 4 TH IMMUNOTHERAPY SEE WHAT INNOVATIONS IN IMMUNOONCOLOGY COULD MEAN FOR YOUR PATIENTS
Our research and development team takes a broad and integrated approach in the development of new immunotherapies. This approach involves leveraging an existing portfolio of molecules that target and modulate the immune-suppressive environment that surrounds tumors. Deep expertise in antibody technology and chemistry helps us develop molecules that effectively modulate T-cell function. We’re also investigating novel approaches to redirect activated T cells to tumors.
To find out more about the immunotherapies we currently have in clinical development, please go to www.Lilly.com.
CZONC00113 01/2017 ELI LILLY ČR, s.r.o., Pobřežní 394/12, 186 00 Praha 8 tel: 234 664 111, fax: 234 664 891.
47532_elonmr_2017_io_journal_ad_fa.indd 1 2/3/17 2:47 PM 20 MARCH 22 2017 PRAGUE CZECH REPUBLIC
www.itoc-conference.eu